Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Protalix BioTherapeutics, Inc. (PLX)

Protalix posts May 2026 corporate presentation with $33.8 million Q1 revenue update

Neutral Impact 2 of 5 other Written later

Protalix BioTherapeutics furnished a May 2026 corporate presentation on its website as Exhibit 99.1 to an 8-K filed May 21, 2026. The deck reiterates Q1 2026 revenue of $33.8 million, including a $25 million Chiesi milestone, and $51.1 million in cash as of March 31, 2026 with no debt. The filing itself contains no new financial results or guidance.

Key points

  • Q1 2026 revenue of $33.8 million, including a $25 million regulatory milestone from Chiesi
  • Cash of $51.1 million as of March 31, 2026; no debt or warrants
  • Approximately 80.5 million shares of common stock outstanding as of May 1, 2026
  • PRX-115 Phase 2 RELEASE trial in uncontrolled gout is enrolling, with top-line results anticipated in 2H 2027

The filing

CompanyProtalix BioTherapeutics, Inc. (PLX)
Form8-K, current report
Filed with the SECMay 21, 2026, 7:03 AM ET
Accession number0001104659-26-064850

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.